Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fennec Pharmaceuticals Inc. - Common Stock (NQ:FENC)

9.700 -0.060 (-0.61%)
Streaming Delayed Price Updated: 3:07 PM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fennec Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fennec Pharmaceuticals Inc. (FENC)
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Fennec Pharmaceuticals Inc. (FENC) Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Fennec Pharmaceuticals Inc. (FENC) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Fennec Pharmaceuticals Inc. (FENC) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Shareholder Alert: Robbins LLP Reminds Investors That Fennec Pharmaceuticals Inc. (FENC) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
News headline image
ROSEN, A LEADING LAW FIRM, Encourages Fennec Pharmaceuticals Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action FENC
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
FENNEC ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Fennec Pharmaceuticals Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Fennec Pharmaceuticals Inc. (FENC) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fennec Pharmaceuticals Inc. (FENC) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Fennec Pharmaceuticals Inc. (FENC) Investors
From Kirby McInerney LLP
Via Business Wire
News headline image
Shareholder Alert: Robbins LLP Informs Investors that Fennec Pharmaceuticals Inc. (FENC) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Fennec Pharmaceuticals Inc. (FENC) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Fennec Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – FENC
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Bronstein, Gewirtz & Grossman, LLC Notifies Fennec Pharmaceuticals Inc. (FENC) Investors of Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) Investor Notice: Investigation over Possible Violations of Securities Laws ↗
San Diego, CA -- (SBWIRE) -- 12/16/2021 -- An investigation for investors in Fennec Pharmaceuticals Inc. (NASDAQ: FENC) shares over potential securities laws violations by Fennec Pharmaceuticals Inc.... 
Via SBWire
News headline image
50 Biggest Movers From Yesterday ↗
Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares surged 121.7% to close at $88.24 on Monday after the company announced positive topline results from the GEM-3 Phase 3 trial... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Dow Jumps 300 Points; Krystal Biotech Shares Spike Higher ↗
Toward the end of trading Monday, the Dow traded up 0.87% to 35,204.42 while the NASDAQ climbed 1.96% to 15,795.08. The S&P also rose, gaining 1.55% to 4,665.67. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
Stocks Rise as "Fear Gauge" Cools Off ↗
The Dow Jones Industrial Average and Nasdaq Composite are both up triple digits midday, paring some of their losses from Friday's massive selloff. 
Via Talk Markets
Topics Stocks
News headline image
Mid-Day Market Update: Crude Oil Rises 4%; Fennec Pharmaceuticals Shares Slide ↗
Midway through trading Monday, the Dow traded up 0.30% to 35,005.10 while the NASDAQ climbed 1.39% to 15,707.48. The S&P also rose, gaining 0.97% to 4,639.11. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
33 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares jumped 116.4% to $86.13 after the company announced positive topline results from the GEM-3 Phase 3 trial of investigational... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Open Higher; Li Auto Sales Top Views ↗
Following the market opening Monday, the Dow traded up 0.22% to 34,977.01 while the NASDAQ climbed 1.53% to 15,727.94. The S&P also rose, gaining 0.92% to 4,637.03. The U.S.... 
Via Benzinga
Topics Stocks
News headline image
Fennec Pharma Stock Plunges On Expected FDA CRL For Pedmark For Chemo-Induced Hearing Issues ↗
Fennec Pharmaceuticals Inc (NASDAQ: FENC) said it expects to receive a Complete Response Letter (CRL) from the FDA regarding its marketing application for Pedmark... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
I hope you got your rest out over the holiday weekend because we're starting off Monday with the biggest pre-market stock movers! 
Via InvestorPlace
News headline image
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting... 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates ↗
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... 
Via Benzinga
News headline image
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21) Agios Pharmaceuticals, Inc... 
Via Benzinga
News headline image
Fennec Pharma Stock Is Trading Higher As Pedmark Is Under FDA Review For Chemo-Induced Toxicity ↗
The FDA has accepted for review Fennec Pharmaceuticals Inc's (NASDAQ: FENC) resubmitted marketing application seeking approval for Pedmark (formulated sodium... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.